Another special purpose acquisition company-related lawsuit has been filed in the Court of Chancery.

But unlike the bulk of the other breach of fiduciary duty SPAC cases that have been brought before the court sporadically since the beginning of the year, this one focuses not on a deal being made hastily, but on allegations that the CEO of the biotech company now known as 180 Life Sciences Corp. knowingly failed to disclose millions of dollars in liability during its negotiation process last year.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]